On August 24, 2022 Neuren Pharmaceuticals Limited ("Neuren" or the "Company") reported this financial report, including the interim consolidated financial statements, for the six months ended 30 June 2022, with the six months ended 30 June 2021 as the comparative period (Press release, Neuren, AUG 24, 2022, View Source;[email protected] [SID1234618610]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Group’s net loss after income tax for the half-year ended 30 June 2022 was $7.0 million, compared with $8.0 million for the half-year ended 30 June 2021.

Research and development costs decreased by $2.4 million, with the higher expenditure in 2021 mainly due to the NNZ2591 Phase 1 clinical trial and manufacture of the drug for clinical trials and non-clinical studies. This was partially offset by an increase in corporate and administrative costs of $0.8 million, due to appointment of new personnel and timing of insurance premiums, and by an increase in share-based payments expense of $0.7 million following the issue of new share options issued in February 2022.

A more detailed discussion of the activities undertaken in the period is set out in the Directors’ Report contained in the attached Interim Report.